Newsroom

Extra! Extra!
Read all about it!

Welcome to our Newsroom, your go-to source for the latest updates on Galapagos. Explore press releases, insightful blogs, and access our resource hub, complete with company materials, designed to provide media and journalists with comprehensive information about our company’s innovations and milestones

Press releasesDownload Center

The latest

Galapagos receives transparency notification from FMR LLC

Pursuant to Belgian transparency legislation, Galapagos received a transparency notification on 30 August 2024 from FMR LLC

Read more

The latest

Galapagos announces FDA clearance of Investigational New Drug (IND) application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Galapagos announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational New Drug (IND) application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL).

Read more

The latest

Galapagos receives transparency notification from FMR LLC

Pursuant to Belgian transparency legislation, Galapagos received a transparency notification on 16 August 2024 from FMR LLC

Read more

STORIES

Press releases

Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received…
View All Press Releases

Follow our journey

Subscribe to receive our press releases

Do you want to stay up to date on our journey, as we are pioneering for patients?

Subscribe to our press releasesContact Media Relations